Abstract
In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.
| Original language | English |
|---|---|
| Pages (from-to) | 11-13 |
| Number of pages | 3 |
| Journal | Multiple Sclerosis and Related Disorders |
| Volume | 9 |
| DOIs | |
| Publication status | Published - Sep 1 2016 |
Fingerprint
Keywords
- Adverse event
- Fingolimod
- Multiple sclerosis
- Respiratory
- Side effect
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. / Bianco, A.; Patanella, A. K.; Nociti, Viviana; De Fino, Chiara; Lucchini, Matteo; Savio, Francesco Lo; Rossini, Paolo Maria; Mirabella, Massimiliano.
In: Multiple Sclerosis and Related Disorders, Vol. 9, 01.09.2016, p. 11-13.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment
AU - Bianco, A.
AU - Patanella, A. K.
AU - Nociti, Viviana
AU - De Fino, Chiara
AU - Lucchini, Matteo
AU - Savio, Francesco Lo
AU - Rossini, Paolo Maria
AU - Mirabella, Massimiliano
PY - 2016/9/1
Y1 - 2016/9/1
N2 - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.
AB - In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.
KW - Adverse event
KW - Fingolimod
KW - Multiple sclerosis
KW - Respiratory
KW - Side effect
UR - http://www.scopus.com/inward/record.url?scp=84974855179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974855179&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2016.06.005
DO - 10.1016/j.msard.2016.06.005
M3 - Article
VL - 9
SP - 11
EP - 13
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
ER -